#USA #3 Boomerang #Pinnaql #Royersford #Pharma Resource Group

Pinnaql Inc. Acquires Pharma Resource Group to Enhance Life Sciences Services

In a significant move for the life sciences sector, Pinnaql, Inc., under the umbrella of 3 Boomerang Capital, LP, has announced its acquisition of Pharma Resource Group, Inc. (PRG), a firm recognized for its expertise in analytical sciences, formulation, and manufacturing advisory services. This strategic acquisition not only marks Pinnaql's third tuck-in purchase within ten months but also exemplifies its commitment to becoming a vital partner for pharmaceutical companies throughout their development processes.

Strategic Importance of the Acquisition

John Duffin, CEO of Pinnaql, emphasized the transformative potential of this acquisition. He noted, "The addition of PRG marks another major step in building Pinnaql into the partner life sciences companies can rely on, from development to commercial readiness." This acquisition allows Pinnaql to integrate PRG’s knowledge in scientific development and scaling processes with its own established competencies in validation, engineering, and regulatory compliance. Consequently, the company is positioned to support clients across various stages of growth, significantly reducing risks associated with execution and compliance.

Founded in 2007, PRG has built a solid reputation by developing strong relationships with pharmaceutical clients, providing specialized advisory in formulation and manufacturing. Its capabilities not only enhance Pinnaql's current service offerings but also broaden its ability to meet the diverse needs of life sciences organizations.

Strengthening a Multi-disciplinary Platform

The acquisition aligns with Pinnaql's overarching goal of establishing a robust, multi-disciplinary platform tailored to address the dynamic requirements of the life sciences field. This follow-up on previous acquisitions, such as that of Validation Engineering Group, Inc., reflects a strategic drive to enhance capabilities in compliance, quality, and technical consulting.

Peter Wen, a principal at 3 Boomerang Capital, highlighted the importance of this growth strategy, stating, "We are pleased to support Pinnaql's ongoing growth through strategic acquisitions that expand its capabilities and market reach." By incorporating PRG into its operations, Pinnaql significantly augments its technical expertise and further differentiates itself in the competitive landscape of life sciences consulting.

Pinnaql’s Commitment to Accelerating Innovation

As a prominent provider of consulting services, Pinnaql is dedicated to delivering solutions that promote innovation and enhance human health across the biopharmaceutical and medical device sectors. The company focuses on operational readiness and minimizing the risks associated with regulatory setbacks. Its mission is to empower clients to concentrate on scientific advancement and patient care in a rapidly evolving environment.

Notably, this latest acquisition empowers Pinnaql to reinforce its status as an essential ally in the journey from laboratory innovations to market-ready therapies. The integration of PRG’s services enables more comprehensive support for clients eager to bring new therapies to the market faster and with greater confidence.

In summary, Pinnaql’s acquisition of Pharma Resource Group stands as a pivotal development in its journey towards becoming a leading, trusted partner in the life sciences sector. It illustrates a proactive approach to meeting the growing demands of pharmaceutical companies, enhancing its portfolio, and ultimately fostering a culture of innovation in medical research and drug development.

For more information on Pinnaql and its services, visit Pinnaql's website.